{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T18:23:28Z","timestamp":1700677408872},"reference-count":36,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2009,3,1]],"date-time":"2009-03-01T00:00:00Z","timestamp":1235865600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2009,3]]},"DOI":"10.1016\/j.clinthera.2009.03.016","type":"journal-article","created":{"date-parts":[[2009,4,23]],"date-time":"2009-04-23T04:28:42Z","timestamp":1240460922000},"page":"668-676","source":"Crossref","is-referenced-by-count":4,"title":["New chemical entities and their market penetration in Finland during the years 1996 through 2005"],"prefix":"10.1016","volume":"31","author":[{"given":"Jaana E.","family":"Martikainen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hannes","family":"Enlund","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2009.03.016_bib1","first-page":"68","article-title":"A review of new drugs in 2004. Floundering innovation and increased risk-taking","volume":"14","year":"2005","journal-title":"Prescrire Int"},{"key":"10.1016\/j.clinthera.2009.03.016_bib3","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1111\/j.1365-2125.2006.02700.x","article-title":"An update on the first decade of the European centralized procedure: How many innovative drugs?","volume":"62","author":"Motola","year":"2006","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2009.03.016_bib4","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1136\/bmj.331.7507.4","article-title":"Drug safety and regulation","volume":"331","author":"Waller","year":"2005","journal-title":"BMJ"},{"key":"10.1016\/j.clinthera.2009.03.016_bib5","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1001\/jama.287.17.2273","article-title":"Safety of newly approved drugs: Implications for prescribing","volume":"287","author":"Temple","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2009.03.016_bib6","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1370\/afm.121","article-title":"Changing prescribing patterns and increasing prescription expenditures in Medicaid","volume":"2","author":"Fink","year":"2004","journal-title":"Ann Fam Med"},{"key":"10.1016\/j.clinthera.2009.03.016_bib7","doi-asserted-by":"crossref","first-page":"29","DOI":"10.2165\/00019053-200422010-00003","article-title":"Why did drug spending increase during the 1990s? A decomposition based on Swedish data","volume":"22","author":"Gerdtham","year":"2004","journal-title":"PharmacoEconomics"},{"issue":"Suppl","key":"10.1016\/j.clinthera.2009.03.016_bib8","doi-asserted-by":"crossref","first-page":"I27","DOI":"10.1097\/01.mlr.0000208132.36055.84","article-title":"Trends in prescription drug expenditures by Medicaid enrollees","volume":"44","author":"Banthin","year":"2006","journal-title":"Med Care"},{"key":"10.1016\/j.clinthera.2009.03.016_bib9","author":"Vogler"},{"key":"10.1016\/j.clinthera.2009.03.016_bib11","series-title":"Finnish Statistics on Medicines 2005","first-page":"79","article-title":"The medicine reimbursement system and reimbursement expenditure in 2005","author":"Enoranta","year":"2006"},{"key":"10.1016\/j.clinthera.2009.03.016_bib12","series-title":"Finnish Statistics on Medicines 2005","first-page":"91","article-title":"Pharmaceuticals Pricing Board, reimbursable medicines and reasonable wholesale prices","author":"Rajaniemi","year":"2006"},{"key":"10.1016\/j.clinthera.2009.03.016_bib13","series-title":"Pharmaca Fennica 1995","year":"1994"},{"key":"10.1016\/j.clinthera.2009.03.016_bib14","series-title":"Pharmaca Fennica 1996","year":"1995"},{"key":"10.1016\/j.clinthera.2009.03.016_bib15","series-title":"Pharmaca Fennica 1997","year":"1996"},{"key":"10.1016\/j.clinthera.2009.03.016_bib16","series-title":"Pharmaca Fennica 1998","year":"1997"},{"key":"10.1016\/j.clinthera.2009.03.016_bib17","series-title":"Pharmaca Fennica 1999","year":"1998"},{"key":"10.1016\/j.clinthera.2009.03.016_bib18","series-title":"Pharmaca Fennica 2000","year":"1999"},{"key":"10.1016\/j.clinthera.2009.03.016_bib19","series-title":"Pharmaca Fennica 2001","year":"2000"},{"key":"10.1016\/j.clinthera.2009.03.016_bib20","series-title":"Pharmaca Fennica 2002","year":"2001"},{"key":"10.1016\/j.clinthera.2009.03.016_bib21","series-title":"Pharmaca Fennica 2003","year":"2002"},{"key":"10.1016\/j.clinthera.2009.03.016_bib22","series-title":"Pharmaca Fennica 2004","year":"2003"},{"key":"10.1016\/j.clinthera.2009.03.016_bib23","series-title":"Pharmaca Fennica 2005","year":"2004"},{"key":"10.1016\/j.clinthera.2009.03.016_bib24","series-title":"Pharmaca Fennica 2006","year":"2005"},{"key":"10.1016\/j.clinthera.2009.03.016_bib25","series-title":"IMS Dataview 7.0. National Pharmacy Database (Finland)","year":"2006"},{"key":"10.1016\/j.clinthera.2009.03.016_bib28","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/BF01989219","article-title":"Therapeutic decision making of physicians","volume":"14","author":"Denig","year":"1992","journal-title":"Pharm Weekbl Sci"},{"key":"10.1016\/j.clinthera.2009.03.016_bib29","series-title":"Regulating Pharmaceuticals in Europe: Striving for Efficiency, Equity and Quality","first-page":"245","article-title":"The off-patent pharmaceutical market","author":"Mrazek","year":"2004"},{"key":"10.1016\/j.clinthera.2009.03.016_bib30","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1111\/j.1524-4733.2008.00331.x","article-title":"Variable access to clopidogrel in harmonized EU market","volume":"11","author":"Stolk","year":"2008","journal-title":"Value Health"},{"key":"10.1016\/j.clinthera.2009.03.016_bib31","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1002\/hec.931","article-title":"The impact of price regulation on the launch delay of new drugs\u2014evidence from twenty-five major markets in the 1990s","volume":"14","author":"Danzon","year":"2005","journal-title":"Health Econ"},{"key":"10.1016\/j.clinthera.2009.03.016_bib32","author":"Riksf\u00f6rs\u00e4krings"},{"key":"10.1016\/j.clinthera.2009.03.016_bib34","author":"Wilking"},{"key":"10.1016\/j.clinthera.2009.03.016_bib36","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s00228-004-0801-9","article-title":"Comparison of national administrative and commercial databases to monitor expenditure and costs of statins across Europe","volume":"60","author":"Walley","year":"2004","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2009.03.016_bib37","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1007\/s00228-003-0634-y","article-title":"Efficacy, safety and cost of new cardiovascular drugs: A survey","volume":"59","author":"Garattini","year":"2003","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2009.03.016_bib38","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1136\/bmj.38582.703866.AE","article-title":"\u201cBreakthrough\u201d drugs and growth in expenditure on prescription drugs in Canada","volume":"331","author":"Morgan","year":"2005","journal-title":"BMJ"},{"key":"10.1016\/j.clinthera.2009.03.016_bib39","author":"Kaplan"},{"key":"10.1016\/j.clinthera.2009.03.016_bib40","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1136\/bmj.326.7386.408","article-title":"Fewer new drugs from the pharmaceutical industry","volume":"326","author":"Taylor","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.clinthera.2009.03.016_bib41","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1377\/hlthaff.25.2.452","article-title":"The quantity and quality of worldwide new drug introductions, 1982\u20132003","volume":"25","author":"Grabowski","year":"2006","journal-title":"Health Aff (Millwood)"},{"key":"10.1016\/j.clinthera.2009.03.016_bib42","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/S1359-6446(05)03524-5","article-title":"Keynote review: Is declining innovation in the pharmaceutical industry a myth?","volume":"10","author":"Schmid","year":"2005","journal-title":"Drug Discov Today"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291809000915?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291809000915?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,20]],"date-time":"2018-12-20T04:25:56Z","timestamp":1545279956000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291809000915"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,3]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009,3]]}},"alternative-id":["S0149291809000915"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2009.03.016","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2009,3]]}}}